Overview

Study of Blinatumomab in Patients With B-cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease

Status:
Recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if Blinacyto (blinatumomab) can help to control ALL with positive MRD. The safety of this drug will also be studied.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Antibodies, Bispecific
Blinatumomab